Salute e Benessere

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025…

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvementFindings to form the basis for a Phase 3 program, anticipated to start in H2 2025PARSIPPANY, N.J. and PARIS, Feb.22, 2025(GLOBE NEWSWIRE)...
Nasdaq GlobeNewswire
22/02/2025

Vascular Access Devices Market to Hit US$9.05 Billion by 2030 with 7.1% CAGR |…

Browse in-depth TOC on 'Vascular Access Devices Market' Browse in-depth TOC on 'Vascular Access Devices Market' 650 - Tables 60 - Figures 350 - Pages Based on type, the vascular access device market is divided into central venous access device, peripheral vascular access device, intraosseous vascular access device, and accessories. Among these, in 2023, the central venous access device segment accounted for the highest market share in the vascular access device market...
PR Newswire
21/02/2025

Ipsen S.A. publishes its 2024 consolidated financial statements

Ipsen S.A. - 2024 Consolidated Financial StatementsAttachment Ipsen_Consolidated financial statements 2024_EN
Nasdaq GlobeNewswire
21/02/2025

Correction: Aino Health year-end report January-December 2024

Correction: The reason for the correction is that the previous mailing did not contain the attached report.This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.Aino reveals the root causes for absence at workOctober - December 2024 Net sales were KSEK 6 000 (6 313)Profit/loss after financial items was KSEK -3 451 (-3 851)Earnings per share were SEK -0,0 (-0,0) January – December 2024...
Nasdaq GlobeNewswire
21/02/2025

Tiziana Life Sciences Announces Agreement for Product Development Services with…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced a product development services agreement with Renaissance Lakewood LLC (“Renaissance”), a leading Contract Development and Manufacturing Organization (CDMO) focused on nasal drug delivery. This collaboration aims to optimize the current formulation and develop a...
Nasdaq GlobeNewswire
21/02/2025

Endo to Report Fourth Quarter and Full Year 2024 Financial Results on March 11…

About EndoEndo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn. About EndoEndo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate...
PR Newswire
21/02/2025

Philips publishes its Annual Report 2024

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2024.Philips' Annual Report 2024 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2025. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course.Philips filed the Annual Report 2024 with the Netherlands Authority for the Financial Markets (AFM) in...
Nasdaq GlobeNewswire
21/02/2025

Change to the Executive Leadership Team

Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Ester Baiget, President & CEO comments:“I want to thank Jacob for his strong leadership and commitment to Novonesis and our Food & Beverage Biosolutions business. Jacob has played an instrumental role in Novonesis. As a result of his contribution, the Food & Beverage Biosolutions business in...
Nasdaq GlobeNewswire
21/02/2025

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available…

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indicationsmatching the reference product Stelara®(ustekinumab) and has granted a provisional determination of interchangeability for SELARSDISELARSDI is the second biosimilar to launch in the U.S. under the Teva and Alvotechstrategic partnership , which includes nine products SELARSDI is ...
Nasdaq GlobeNewswire
21/02/2025

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available…

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indicationsmatching the reference product Stelara ® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDISELARSDI is the second biosimilar to launch in the U.S. under the Teva and Alvotech strategic partnership , which includes nine products SELARSDI is approved for the treatment of moderate to severe plaque...
Nasdaq GlobeNewswire
21/02/2025

UNION therapeutics announces presentation of preliminary data from Phase 2a…

Poster details Poster details Poster title: Orismilast for the Treatment of Moderate to Severe Ulcerative Colitis: A phase 2a, open-label, single-arm explorative clinical study Authors: Trine Velte Honoré,Flemming Bendtsen, Jakob Seidelin,Johan Burisch Kim Kjøller, Chief Executive Officer of UNION therapeutics said: "We are encouraged by the investigators' presentation of preliminary data on orismilast for the treatment of ulcerative colitis at the ECCO congress...
PR Newswire
21/02/2025

Philips and Mass General Brigham announce collaboration to improve patient care…

Integrating advanced data analytics into clinical practice to improve patient care Amsterdam, The Netherlands and Cambridge, MA –Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, and Mass General Brigham (MGB), home to one of the largest hospital system-based research enterprises in the US, today announced a new collaboration to develop and deploy advanced data infrastructure and AI designed to integrate and process live healthcare data from a wide range of...
Nasdaq GlobeNewswire
21/02/2025

Aino Health year-end report January-December 2024

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.Aino reveals the root causes for absence at workOctober - December 2024Net sales were KSEK 6 000 (6 313)Profit/loss after financial items was KSEK -3 451 (-3 851)Earnings per share were SEK -0,0 (-0,0)January – December 2024Net sales were KSEK 23 941 (23 918)Profit/loss after financial items was KSEK -9 915 (-10 661)...
Nasdaq GlobeNewswire
21/02/2025

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs…

Put Option Agreements signed to date with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs2025 OCEANEs holders' general meeting convened for March 10, 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option...
Nasdaq GlobeNewswire
21/02/2025

New study shows significant improved clinical accuracy with Nevisense for both…

"It is an interesting article showing the positive effects of adding Nevisense and EIS as a decision support tool. Cultural differences can also be seen between German and US physicians where US dermatologist's are more afraid to miss a melanoma and therefore have a higher biopsy rate while in Germany they try to avoid unnecessary biopsies. The key message is that Nevisense can secure a better decision for the patient," says Pia Renaudin, CEO of SciBase. " It is an interesting…
PR Newswire
21/02/2025

Bracco and the European Society of Radiology build on long-standing partnership…

MILAN, Feb. 21, 2025 /PRNewswire/ -- Bracco, a world leader in diagnostic imaging, announced today that it will showcase an innovative and immersive experience that brings the concept of sustainability to life and expands on "Planet Radiology" – a campaign launched by the European Society of Radiology (ESR), a nonprofit professional organization dedicated to strengthening and unifying European radiology, at the European Congress of Radiology, taking place in Vienna from February 26 to…
PR Newswire
21/02/2025

Alamar Biosciences Launches Certified Service Provider Program to Expand Access…

Currently, six distinguished service provider laboratories have received CSP certification to date and are actively accepting projects, including: Currently, six distinguished service provider laboratories have received CSP certification to date and are actively accepting projects, including: "We are thrilled to launch the Certified Service Provider Program to make our NULISA technology more accessible to the research community," saidYuling Luo, Ph.D., Founder, Chairman and CEO of…
PR Newswire
20/02/2025

Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by…

Key Takeaways from the Influenza Vaccine Market Report Key Takeaways from the Influenza Vaccine Market Report To read more about the latest highlights related to the influenza vaccine market, get a snapshot of the key highlights entailed in theGlobal Influenza Vaccine Market Report Influenza Vaccine Overview The influenza vaccine is a crucial preventive measure against the seasonal flu, which is caused by influenza viruses that mutate frequently. The vaccine is updated...
PR Newswire
20/02/2025

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care…

About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and…
PR Newswire
20/02/2025

Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70…

This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the...
Nasdaq GlobeNewswire
20/02/2025

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical…

Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 studyPositive results could support the initiation of a pivotal Phase 3 trial in patients in Japan with MASHThe study represents the first significant step of Inventiva's and Hepalys's partnership toward the development of lanifibranor in Japan and South KoreaDaix (France), New York City (New York, United States), Tokyo (Japan), February 20, 2025– Inventiva...
Nasdaq GlobeNewswire
20/02/2025

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for…

NEW YORK and VIENNA, Austria, Feb.20, 2025(GLOBE NEWSWIRE) --NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014,...
Nasdaq GlobeNewswire
20/02/2025

Roche unveils a new class of next-generation sequencing with its novel…

Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immune disorders and neurodegenerative conditionsCombined with an innovative, high throughput sensor module, SBX uses expanded synthetic molecules to determine the DNA sequence of a target molecule, creating an ultra-rapid, scalable and flexible technologyReducing the time from sample to...
Nasdaq GlobeNewswire
20/02/2025

Notice convening the Annual General Meeting 2025 of Essity Aktiebolag (publ)

A. Right to participate at the Meeting A. Right to participate at the Meeting Shareholders who wish to participate in the Annual General Meeting must For shareholders who have their shares registered through a bank or other nominee, the following applies in order to be entitled to participate in the Meeting. In addition to giving notice of participation, such shareholder must re-register its shares in its own name so that the shareholder is listed in the presentation of the share...
PR Newswire
20/02/2025
Altri  Comunicati